User menu

Combination of paclitaxel and LAG3-Ig (IMP321), a novel MHC class II agonist, as a first-line chemoimmunotherapy in patients with metastatic breast carcinoma (MBC): interim results from the run-in phase of a placebo controlled randomized phase II

Bibliographic reference Duhoux, François ; Jager, Agnes ; Dirix, Luc ; Huizing, Manon ; Jerusalem, Guy ; et. al. Combination of paclitaxel and LAG3-Ig (IMP321), a novel MHC class II agonist, as a first-line chemoimmunotherapy in patients with metastatic breast carcinoma (MBC): interim results from the run-in phase of a placebo controlled randomized phase II.Annual Meeting of the American Society of Clinical Oncology (ASCO) (Chicago, IL, USA , 04/06/2017). In: Journal of Clinical Oncology, Vol. 35, no.suppl, p. abstr 1062 (2017)
Permanent URL http://hdl.handle.net/2078.1/186103